A novel AAV Vector for gene therapy of RPE-related retinal degenerative diseases via intravitreal delivery

Abstract

To the editor,

Dysfunction of retinal pigment epithelium (RPE) cells leads to multiple blinding retinal degenerative diseases, including retinitis pigmentosa, age-related macular degeneration, and Stargardt disease [1]. Currently, no drug treatments are available to cure or slow the progression of these diseases, and gene therapy has been considered a promising approach. However, when delivered via intravitreal injection, commonly used vectors like AAV2 and AAV9 exhibit poor transduction rates in RPE cells. Subretinal injection, while more effective, requires sophisticated surgical skills and carries risks, such as retinal tears and detachments [2]. Therefore, developing a highly efficient RPE-specific AAV variant for intravitreal injection would be invaluable for gene therapy of RPE-related retinal degenerative diseases.

To identify such an AAV variant, we conducted a multi-round in vivo screening by intravitreal injection in mice with a randomized 9-mer library (diversity of 1.34E6), inserted between positions 587–588 of AAV2 capsid (Fig. 1A). We analyzed NGS data of collected viral genomes from three rounds of screening based on their read counts and enrichment scores, ultimately identifying 10 candidate variants (Supplemental Fig. 1A-I). Preliminary validation in mice revealed a variant with specific transduction for RPE cells, named AAV206 (Supplemental Fig. 1J). We then characterized the transduction properties of AAV206 in detail. Mice received intravitreal injections of AAV2-GFP and AAV206-GFP, and subsequent analysis of whole mounts of the RPE-choroid-sclera complex and retina showed that AAV2-GFP predominantly transduced neuroretinal cells with negligible transduction of RPE cells. In contrast, AAV206-GFP efficiently and specifically transduced RPE cells with minimal neuroretinal transduction (Fig. 1B-D). Consistent with these findings, frozen sections of the retina revealed that AAV2-GFP expression was mainly observed in retinal ganglion cell layer and inner nuclear layer, whereas AAV206-GFP specifically transduced RPE cells (Fig. 1E-F).

Fig. 1

A novel RPE-specific AAV vector. (A) Schematic diagram of AAV vectors screened for specific targeting of RPE cells. (B) Whole mounts of mice retina and RPE-Choroid-Sclera after intravitreal injection of AAV2-GFP or AAV206-GFP for 14 days. GFP expression (green) indicates positively transduced cells. RPE cells are marked by ZO-1 (red). Scale bar: 1000 μm (left panel), 20 μm (right panel). (C, D) Statistical results of GFP fluorescence areas in RPE (C) and retinal (D) tissues from (B). n = 8 eyes, ****P < 0.0001 by Student’s t-test; values shown as mean ± SD. (E) Frozen sections of mice retina 14 days post-transduction with AAV2-GFP or AAV206-GFP. n = 6 eyes, Scale bar: 1000 μm (low magnification), 40 μm (high magnification). (F) Quantification of GFP fluorescence intensity in (E) using ImageJ. (G) CNV was examined in vivo by OCT after the induction of CNV for 7 days. Scale bar: 200 μm. (H, I) Measurements of CNV lesion length (yellow dotted line) and thickness (red dotted line) from OCT. n = 8 eyes, ****P < 0.0001 by one-way ANOVA; values shown as mean ± SD. (J) FFA to detect CNV lesion leakage, with representative color fundus photographs (CFP) and FFA images for each group after the induction of CNV for 7 days. (K) Distribution of CNV lesion grades. *P < 0.05, ****P < 0.0001 by the Kruskal-Wallis test. (L) RPE-choroid-sclera whole mounts stained with IB4 (red) to measure CNV areas after the induction of CNV for 7 days, with microglia marked by iba1 (green). Scale bar: 1000 μm (low magnification), 100 μm (high magnification). (M) Quantification of CNV areas in (L) using ImageJ. n = 8 eyes, **P < 0.01, ****P < 0.0001 by one-way ANOVA; values shown as mean ± SD

Full size image

Additionally, we investigated the toxicity and immunogenicity of AAV206 vector. Fourteen days after intravitreal injection of AAV2 and AAV206, electroretinography results revealed no significant changes in a-wave amplitudes in either group. However, AAV2 group, but not AAV206 group, showed a significant reduction in b-wave amplitude (Supplemental Fig. 2A-C). Despite this, neither group exhibited obvious retinal degeneration (Supplemental Fig. 2D-E). To further assess the immunogenicity of both vectors, we performed RNA sequencing. The volcano plot demonstrated 898 upregulated and 915 downregulated genes in AAV206 group compared to AAV2 group (adj.P.val < 0.05, absolute logFC > 0.2) (Supplemental Fig. 2F). Gene set enrichment analysis (GSEA) indicated that the top 15 suppressed biological processes were mainly related to immune response (Supplemental Fig. 2G). Further hallmark gene-set analysis revealed that the top 15 suppressed pathways were primarily enriched in inflammatory pathways such as IL6/JAK/STAT3 and TNFα/NF-κB (Supplemental Fig. 2H). Consistently, immunofluorescence staining showed fewer activated microglia in AAV206-GFP group compared to AAV2-GFP group (Supplemental Fig. 2I-J). Together, these findings indicate that AAV206 exhibits lower retinal toxicity and immunogenicity compared to AAV2.

To explore the gene therapy efficacy of AAV206 vector in RPE-related retinal degenerative diseases via intravitreal injection, we employed a laser-induced choroidal neovascularization (CNV) mouse model for wet AMD. In this type of AMD, dysfunctional RPE cells abnormally produce VEGF, leading to pathological CNV, which can cause vascular leakage or hemorrhage in the subretinal space, ultimately resulting in retinal degeneration [3]. Given that the soluble VEGF receptor, sFlt-1, can neutralize VEGF, and that AAV2-sFLT-based gene therapy via intravitreal injection has already shown promise in treating wet AMD [4], we compared the treatment effects of intravitreal injection of AAV206-sFLT and AAV2-sFLT in wet AMD. The results from optical coherence tomography (OCT) and fluorescein fundus angiography (FFA) demonstrated that both AAV2-sFLT and AAV206-sFLT significantly reduced CNV size and leakage in vivo. However, AAV206-sFLT exhibited stronger effects on both CNV size and leakage compared to AAV2-sFLT (Fig. 1G-K). Consistently, immunofluorescence staining showed that both AAV2-sFLT and AAV206-sFLT significantly reduced CNV size, with AAV206-sFLT demonstrating superior efficacy (Fig. 1L-M). Thus, although AAV2 has demonstrated promising efficacy in CNV treatment, AAV206 may achieve better therapeutic effects with less impact on the retina.

In summary, we have identified a novel RPE-specific AAV vector, AAV206, developed through random mutations in AAV2. Delivered via intravitreal injection, AAV206 transduces RPE cells with high specificity and efficiency while exhibiting low retinal toxicity and immunogenicity compared to the conventional AAV2 vector. Moreover, we demonstrated that AAV206-sFLT, when injected intravitreally, provides superior inhibition of CNV formation compared to AAV2-sFLT in a laser-induced CNV mouse model. Whether AAV206 also shows similar efficacy in other animal models, such as non-human primates, requires further investigation. Nevertheless, these findings suggest that AAV206 vector represents a valuable tool for studying RPE biology and holds promise as an intravitreal delivery vector for treating RPE-related retinal degenerative diseases.

All data generated or analyzed during this study are included in this published article and its supplementary information files. Bulk RNA-seq raw data has been deposited into the GEO database (accession number: GSE271661).

1. Zarbin M. Cell-based therapy for degenerative retinal disease. Trends Mol Med. 2016;22(2):115–34.

   Article PubMed Google Scholar

2. DiCarlo JE, Mahajan VB, Tsang SH. Gene therapy and genome surgery in the retina. J Clin Invest. 2018;128(6):2177–88.

   Article PubMed PubMed Central Google Scholar

3. Fleckenstein M, Keenan TDL, Guymer RH, Chakravarthy U, Schmitz-Valckenberg S, Klaver CC, Wong WT, Chew EY. Age-related macular degeneration. Nat Rev Dis Primer. 2021;7(1):1–25.

   Google Scholar

4. Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Lancet. 2017;390(10089):50–61.

   Article CAS PubMed Google Scholar

Download references

Not applicable.

This study was supported by the Key Research and Development Program of the Ministry of Science and Technology (2022YFF1202901; 2023YFC3403400), the National Natural Science Foundation of China (82171404), the Natural Science Foundation of Guangdong Province of China (2023A1515011529), the Science and Technology Planning Project of Guangzhou City (2023A03J0181, 2024A04J6481), the Fundamental Research Funds for the Central Universities (22yklj04), Shanghai Frontiers Science Center for Biomacromolucules and Precision Medicine, the Double First-Class Initiative Fund of ShanghaiTech University, Shanghai Local College Capacity Building Project (22010202700) and the Research Start-up Founds of Sun Yat-sen University (Funded Talent[2020]18).

Author notes

1. Yajun Gong and Xianyu Huang contributed equally to this work.

Authors and Affiliations

1. State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University, 54 Xianlie South Rd, Guangzhou, 510060, China

   Yajun Gong, Tianxiang Tu, Xin Fu, Ruobi Li & Xiaolai Zhou

2. Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Sun Yat-Sen University, Guangzhou, 510060, China

   Yajun Gong, Tianxiang Tu, Xin Fu, Ruobi Li & Xiaolai Zhou

3. Shanghai EmayGene Biotech Co. Ltd, Shanghai, 201203, China

   Xianyu Huang & Yushun Yuan

4. iHuman Institute, ShanghaiTech University, Shanghai, 201210, China

   Cenfeng Chu, Chunrui Xian & Guisheng Zhong

5. School of Life Science and Technology, ShanghaiTech University, Shanghai, 201210, China

   Cenfeng Chu, Chunrui Xian & Guisheng Zhong

Authors

1. Yajun GongView author publications

   You can also search for this author in PubMed Google Scholar

2. Xianyu HuangView author publications

   You can also search for this author in PubMed Google Scholar

3. Tianxiang TuView author publications

   You can also search for this author in PubMed Google Scholar

4. Cenfeng ChuView author publications

   You can also search for this author in PubMed Google Scholar

5. Chunrui XianView author publications

   You can also search for this author in PubMed Google Scholar

6. Yushun YuanView author publications

   You can also search for this author in PubMed Google Scholar

7. Xin FuView author publications

   You can also search for this author in PubMed Google Scholar

8. Ruobi LiView author publications

   You can also search for this author in PubMed Google Scholar

9. Guisheng ZhongView author publications

   You can also search for this author in PubMed Google Scholar

10. Xiaolai ZhouView author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Y.G., X.Y. designed and performed experiments, analyzed the data and wrote the manuscript. T.T., C.C., and C.X. performed data analysis and edited the paper. Y.Y. and X.F. helped with data analysis and reviewed the manuscript. X.Z. and G.Z. conceived the study, supervised the whole project, and wrote the manuscript. All authors approved the final manuscript.

Corresponding authors

Correspondence to Guisheng Zhong or Xiaolai Zhou.

Ethics approval and consent to participate

All animal experiments were carried out with the approval of the Institutional Animal Care and Use Committee of Sun Yat-Sen University (Permit Number: SYSU-IACUC-2024-002111) and in compliance with the ARVO statement for the use of animals in ophthalmic and vision research.

Consent for publication

All authors have reviewed the final manuscript and consented to publication.

Competing interests

The authors have declared that no competing interests exists.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Below is the link to the electronic supplementary material.

Supplementary Material 1

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

Cite this article

Gong, Y., Huang, X., Tu, T. et al. A novel AAV Vector for gene therapy of RPE-related retinal degenerative diseases via intravitreal delivery. Mol Neurodegeneration 19, 89 (2024). https://doi.org/10.1186/s13024-024-00777-x

Download citation

• Received: 12 August 2024

• Accepted: 08 November 2024

• Published: 25 November 2024

• DOI: https://doi.org/10.1186/s13024-024-00777-x

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative

Keywords

• Retinal pigment epithelium (RPE)
• Adeno-associated virus (AAV)
• Gene therapy
• Retinal degenerative diseases
• Age-related macular degeneration (AMD)